(Q48005460)

English

A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial

scientific article published in January 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23801256

A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23801256

0 references

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23801256

author name string

Ahmad Ghanizadeh

1

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23801256

Aliakbar Sahraeizadeh

2

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23801256

publication date

1 January 2014

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23801256

Child Psychiatry and Human Development

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23801256

45

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23801256

2

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23801256

185-192

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23801256

https://scigraph.springernature.com/pub.10.1007/s10578-013-0390-x

0 references

Global prevalence of autism and other pervasive developmental disorders

1 reference

https://api.crossref.org/works/10.1007%2FS10578-013-0390-X

21 January 2018

Estimated prevalence of autism spectrum conditions in Cambridgeshire is over 1%.

1 reference

https://api.crossref.org/works/10.1007%2FS10578-013-0390-X

21 January 2018

Glutathione-related factors and oxidative stress in autism, a review

1 reference

https://api.crossref.org/works/10.1007%2FS10578-013-0390-X

21 January 2018

A systematic review of medical treatments for children with autism spectrum disorders

1 reference

https://api.crossref.org/works/10.1007%2FS10578-013-0390-X

21 January 2018

Aripiprazole for the treatment of irritability associated with autism

1 reference

https://api.crossref.org/works/10.1007%2FS10578-013-0390-X

21 January 2018

Atomoxetine for treating ADHD symptoms in autism: a systematic review

1 reference

https://api.crossref.org/works/10.1007%2FS10578-013-0390-X

21 January 2018

Hyperbaric oxygen therapy for treatment of children with autism: a systematic review of randomized trials

1 reference

https://api.crossref.org/works/10.1007%2FS10578-013-0390-X

21 January 2018

A double-blind placebo controlled trial of Ginkgo biloba added to risperidone in patients with autistic disorders.

1 reference

https://api.crossref.org/works/10.1007%2FS10578-013-0390-X

21 January 2018

Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism.

1 reference

https://api.crossref.org/works/10.1007%2FS10578-013-0390-X

21 January 2018

Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder

1 reference

https://api.crossref.org/works/10.1007%2FS10578-013-0390-X

21 January 2018

Atypical antipsychotic medications in the management of disruptive behaviors in children: safety guidelines and recommendations

1 reference

https://api.crossref.org/works/10.1007%2FS10578-013-0390-X

21 January 2018

Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents

1 reference

https://api.crossref.org/works/10.1007%2FS10578-013-0390-X

21 January 2018

Acute and long-term safety and tolerability of risperidone in children with autism

1 reference

https://api.crossref.org/works/10.1007%2FS10578-013-0390-X

21 January 2018

Aripiprazole: in the treatment of irritability associated with autistic disorder in pediatric patients

1 reference

https://api.crossref.org/works/10.1007%2FS10578-013-0390-X

21 January 2018

Aripiprazole in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder: results from a 52-week, open-label study

1 reference

https://api.crossref.org/works/10.1007%2FS10578-013-0390-X

21 January 2018

Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6-17 years old):results from a pooled analysis of 2 studies

1 reference

https://api.crossref.org/works/10.1007%2FS10578-013-0390-X

21 January 2018

Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders

1 reference

https://api.crossref.org/works/10.1007%2FS10578-013-0390-X

21 January 2018

Effect of aripiprazole 2 to 15 mg/d on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post hoc analysis of two controlled trials

1 reference

https://api.crossref.org/works/10.1007%2FS10578-013-0390-X

21 January 2018

Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents

1 reference

https://api.crossref.org/works/10.1007%2FS10578-013-0390-X

21 January 2018

Risperidone for autism spectrum disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/23801256

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23801256

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting the mitochondrial electron transport chain in autism, a systematic review and synthesis of a novel therapeutic approach

1 reference

https://pubmed.ncbi.nlm.nih.gov/23801256

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23801256

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10578-013-0390-X

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23801256

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23801256

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48005460&oldid=2182835189"